OLBETAM

This brand name is authorized in Netherlands, New Zealand, Singapore, South Africa, UK.

Active ingredients

The drug OLBETAM contains one active pharmaceutical ingredient (API):

1	Acipimox UNII K9AY9IR2SD - ACIPIMOX
	Acipimox inhibits the release of fatty acids from adipose tissue and reduces the blood concentrations of very low density lipoproteins (VLDL or Pre-beta) and low density lipoproteins (LDL or beta) with a subsequent overall reduction in triglyceride and cholesterol levels.
	Read more about Acipimox

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
OLBETAM Capsule	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
C10AD06	Acipimox	C Cardiovascular system → C10 Lipid modifying agents → C10A Lipid modifying agents, plain → C10AD Nicotinic acid and derivatives
Discover more medicines within C10AD06

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
GB	Medicines & Healthcare Products Regulatory Agency	146678, 36984
NL	Z-Index G-Standaard, PRK	33030
NZ	Medicines and Medical Devices Safety Authority	4770
SG	Health Sciences Authority	04543P
ZA	Health Products Regulatory Authority	W/7.5/365